AR036604A1 - Derivados de 4-pirimidona 3-sustituida - Google Patents
Derivados de 4-pirimidona 3-sustituidaInfo
- Publication number
- AR036604A1 AR036604A1 ARP020103547A ARP020103547A AR036604A1 AR 036604 A1 AR036604 A1 AR 036604A1 AR P020103547 A ARP020103547 A AR P020103547A AR P020103547 A ARP020103547 A AR P020103547A AR 036604 A1 AR036604 A1 AR 036604A1
- Authority
- AR
- Argentina
- Prior art keywords
- substituted
- ring
- alkyl group
- atom
- group
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/34—One oxygen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/56—One oxygen atom and one sulfur atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Ophthalmology & Optometry (AREA)
- Hematology (AREA)
- Psychiatry (AREA)
- Obesity (AREA)
- Hospice & Palliative Care (AREA)
- Endocrinology (AREA)
- Oncology (AREA)
- Child & Adolescent Psychology (AREA)
- Emergency Medicine (AREA)
- Psychology (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
Un derivado de pirimidona representado por la fórmula (1) o una sal del mismo, o un solvato del mismo, o un hidrato del mismo que tiene una actividad inhibidora contra la cinasa proteínica tau 1. También se reivindican un medicamento y un inhibidor de la cinasa proteínica tau 1. Dicho medicamento se usa para el tratamiento preventivo y/o terapéutico de una enfermedad causada por la hiper actividad de la cinasa proteínica tau 1, tales como: mal de Alzheimer, accidentes cerebrovasculares isquémicos, síndrome de Down, complejo de demencia y parkinsonismo de Guam, demencia vascular, danos traumáticos, traumas cerebrales y de la médula espinal, retinopatía y glaucoma. Reivindicación 1: Un derivado de pirimidona representado por la fórmula (1) o una sal del mismo, o un solvato del mismo, o un hidrato del mismo, caracterizada porque R1 representa un grupo alquilo C1-12 que puede ser sustituido; R representa cualquiera de los grupos representados por las siguientes fórmulas (2) a (5) caracterizadas porque R2 y R3 independientemente representan un átomo de hidrógeno o un grupo alquilo C1-8; R4 representa un anillo de benceno que puede ser sustituido, un anillo de naftaleno que puede ser sustituido, un anillo de indano que puede ser sustituido, un anillo de tetrahidronaftaleno que puede ser sustituido, o un anillo heterocíclico opcionalmente sustituido que tiene de 1 a 4 heteroátomos seleccionados del grupo que consiste de un átomo de oxígeno, un átomo de azufre, un átomo de nitrógeno, y tiene de 5 a 10 átomos, en total. R5 representa un grupo alquilo C1-8 que puede ser sustituido, un grupo cicloalquilo C3-8 que puede ser sustituido, un anillo de benceno que puede ser sustituido, un anillo de naftaleno que puede ser sustituido, un anillo de indano que puede ser sustituido, un anillo de tetrahidronaftaleno que puede ser sustituido, o un anillo heterocíclico opcionalmente sustituido que tiene de 1 a 4 heteroátomos seleccionados del grupo que consiste de un átomo de oxígeno, un átomo de azufre, un átomo de nitrógeno, y tiene de 5 a 10 átomos, en total. R6 representa un átomo de hidrógeno, un grupo alquilo C1-8 que puede ser sustituido, un anillo de benceno que puede ser sustituido; ó R5 y R6 pueden unirse para formar, junto con el carbono al cual se unen, un anillo espiro cíclico opcionalmente sustituido, que tiene de 3 a 11 átomos, en total, que constituyen el anillo; R7 y R8 independientemente representan un átomo de hidrógeno, o un grupo alquilo C1-8, o R7 y R8 pueden combinarse para formar un grupo alquileno C2-6; R9 y R10 representan un grupo alquilo C1-8 que puede ser sustituido, un grupo cicloalquilo C3-8 que puede ser sustituido, un anillo de benceno que puede ser sustituido, un anillo de naftaleno que puede ser sustituido, o un anillo heterocíclico opcionalmente sustituido que tiene de 1 a 4 heteroátomos seleccionados del grupo que consiste de un átomo de oxígeno, un átomo de azufre, un átomo de nitrógeno, y tiene de 5 a 10 átomos, en total, o R9 y R10 representan -N(R11)R12) caracterizados porque R11 representa un átomo de hidrógeno, un grupo alquilo C1-8; y R12 representa un grupo alquilo C1-8, un anillo de benceno que puede ser sustituido, un anillo de naftaleno que puede ser sustituido, o un anillo heterocíclico opcionalmente sustituido que tiene de 1 a 4 heteroátomos seleccionados del grupo que consiste de un átomo de oxígeno, un átomo de azufre, un átomo de nitrógeno, y que tiene de 5 a 10 átomos en total, que constituyen el anillo; y X representa CH2, O ó NR13 caracterizados porque R13 representa un átomo de hidrógeno o un grupo alquilo C1-8.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2001331674 | 2001-09-21 | ||
JP2001331675 | 2001-09-21 | ||
JP2001331676 | 2001-09-21 | ||
JP2001331678 | 2001-09-21 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR036604A1 true AR036604A1 (es) | 2004-09-22 |
Family
ID=27482650
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP020103546A AR043700A1 (es) | 2001-09-21 | 2002-09-20 | Derivados de 3-substituida-4-pirimidona |
ARP020103547A AR036604A1 (es) | 2001-09-21 | 2002-09-20 | Derivados de 4-pirimidona 3-sustituida |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP020103546A AR043700A1 (es) | 2001-09-21 | 2002-09-20 | Derivados de 3-substituida-4-pirimidona |
Country Status (24)
Country | Link |
---|---|
US (1) | US7572793B2 (es) |
EP (1) | EP1427709B1 (es) |
JP (1) | JP4368682B2 (es) |
KR (1) | KR100754596B1 (es) |
CN (1) | CN1319950C (es) |
AR (2) | AR043700A1 (es) |
AT (1) | ATE312827T1 (es) |
AU (1) | AU2002337498B2 (es) |
BR (1) | BR0212893A (es) |
CA (1) | CA2460177C (es) |
CY (1) | CY1105554T1 (es) |
DE (1) | DE60208051T2 (es) |
DK (1) | DK1427709T3 (es) |
EA (1) | EA007224B1 (es) |
ES (1) | ES2256540T3 (es) |
HK (1) | HK1068608A1 (es) |
HU (1) | HUP0401898A3 (es) |
IL (2) | IL160701A0 (es) |
MX (1) | MXPA04002661A (es) |
NO (1) | NO326694B1 (es) |
NZ (1) | NZ531637A (es) |
PL (1) | PL368816A1 (es) |
TW (1) | TWI303171B (es) |
WO (1) | WO2003027080A1 (es) |
Families Citing this family (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AR023052A1 (es) | 1998-09-25 | 2002-09-04 | Mitsuharu Yoshimura Milton | Derivados de pirimidona |
JP4347050B2 (ja) | 2001-09-21 | 2009-10-21 | 田辺三菱製薬株式会社 | 3−置換−4−ピリミドン誘導体 |
NZ541074A (en) * | 2002-12-16 | 2008-04-30 | Mitsubishi Pharma Corp | 3-Substituted-4-pyrimidone derivatives |
KR20050122220A (ko) | 2003-03-25 | 2005-12-28 | 다케다 샌디에고, 인코포레이티드 | 디펩티딜 펩티다제 억제제 |
TWI357408B (en) * | 2003-03-26 | 2012-02-01 | Mitsubishi Tanabe Pharma Corp | 3-substituted-4-pyrimidone derivatives |
RU2006107553A (ru) | 2003-08-13 | 2007-09-20 | Такеда Фармасьютикал Компани Лимитед (Jp) | Производные 4-пиримидона и их применение в качестве ингибиторов пептидилпептидаз |
US7790734B2 (en) | 2003-09-08 | 2010-09-07 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
GB0325956D0 (en) | 2003-11-06 | 2003-12-10 | Addex Pharmaceuticals Sa | Novel compounds |
EA013427B1 (ru) | 2004-03-15 | 2010-04-30 | Такеда Фармасьютикал Компани Лимитед | Ингибиторы дипептидилпептидазы |
TW200621760A (en) * | 2004-09-09 | 2006-07-01 | Mitsubishi Pharma Corp | 2-morpholino-4-pyrimidone compound |
US8129377B2 (en) | 2004-09-29 | 2012-03-06 | Mitsubishi Tanabe Pharma Corporation | 6-(pyridinyl)-4-pyrimidone derivates as tau protein kinase 1 inhibitors |
JP2008524331A (ja) | 2004-12-21 | 2008-07-10 | 武田薬品工業株式会社 | ジペプチジルペプチダーゼ阻害剤 |
GB0510142D0 (en) * | 2005-05-18 | 2005-06-22 | Addex Pharmaceuticals Sa | Novel compounds A1 |
GB0510141D0 (en) * | 2005-05-18 | 2005-06-22 | Addex Pharmaceuticals Sa | Novel compounds B3 |
TW200740779A (en) * | 2005-07-22 | 2007-11-01 | Mitsubishi Pharma Corp | Intermediate compound for synthesizing pharmaceutical agent and production method thereof |
ME02005B (me) | 2005-09-14 | 2012-08-31 | Takeda Pharmaceuticals Co | Inhibitori dipeptidil peptidaze za lečenje dijabetesa |
CN101360723A (zh) | 2005-09-16 | 2009-02-04 | 武田药品工业株式会社 | 制备嘧啶二酮衍生物的方法 |
TW200813015A (en) * | 2006-03-15 | 2008-03-16 | Mitsubishi Pharma Corp | 2-(cyclic amino)-pyrimidone derivatives |
CN101528729A (zh) * | 2006-08-23 | 2009-09-09 | 辉瑞产品公司 | 作为gsk-3抑制剂的嘧啶酮化合物 |
US8324383B2 (en) | 2006-09-13 | 2012-12-04 | Takeda Pharmaceutical Company Limited | Methods of making polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile |
TW200838536A (en) | 2006-11-29 | 2008-10-01 | Takeda Pharmaceutical | Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor |
AR064660A1 (es) * | 2006-12-26 | 2009-04-15 | Mitsubishi Tanabe Pharma Corp | Derivados de pirimidinona 6-heterociclica 2-sustituida, medicamentos que los contienen y usos para prevenir y/o tratar enfermedades neurodegenerativas entre otras |
US8093236B2 (en) | 2007-03-13 | 2012-01-10 | Takeda Pharmaceuticals Company Limited | Weekly administration of dipeptidyl peptidase inhibitors |
WO2009035159A1 (en) * | 2007-09-14 | 2009-03-19 | Mitsubishi Tanabe Pharma Corporation | 3-methyl-2- ( (2s) -2- (4- (3-methyl-l, 2, 4-0xadiaz0l-5-yl) phenyl) morpholino) -6- (pyrimidin-4-yl) pyrimidin-4 (3h) -one as tau protein kinase inhibitor |
AU2008297817A1 (en) * | 2007-09-14 | 2009-03-19 | Mitsubishi Tanabe Pharma Corporation | 6-pyrimidinyl-pyrimid-4-one derivative |
EP2078717A1 (en) | 2008-01-11 | 2009-07-15 | sanofi-aventis | 6-Pyrimidinyl-pyrimid-2-one derivative |
AR076014A1 (es) | 2009-04-02 | 2011-05-11 | Sanofi Aventis | Derivados de 3- (1,4) oxazepan -4-pirimidona |
JP5535310B2 (ja) * | 2009-08-13 | 2014-07-02 | 田辺三菱製薬株式会社 | タウプロテインキナーゼ1阻害剤としてのピリミドン誘導体 |
EP2464639A1 (en) | 2009-08-13 | 2012-06-20 | Mitsubishi Tanabe Pharma Corporation | Pyrimidone derivatives used as tau protein kinase 1 inhibitors |
EP2550361B1 (en) | 2010-03-25 | 2017-02-08 | The J. David Gladstone Institutes | Compositions and methods for treating neurological disorders |
WO2012145169A2 (en) | 2011-04-21 | 2012-10-26 | The Regents Of The University Of California | Functionalized magnetic nanoparticles and use in imaging amyloid deposits and neurofibrillary tangles |
ES2554843T3 (es) * | 2012-01-12 | 2015-12-23 | F. Hoffmann-La Roche Ag | Derivados heterocíclicos como receptores asociados de trazas de amina (TAARs) |
WO2014028777A2 (en) | 2012-08-16 | 2014-02-20 | Ipierian, Inc. | Methods of treating a tauopathy |
AU2013334229B2 (en) | 2012-10-25 | 2018-02-15 | Bioverativ Usa Inc. | Anti-complement C1s antibodies and uses thereof |
RS63212B1 (sr) | 2012-11-02 | 2022-06-30 | Bioverativ Usa Inc | Antikomplementna c1s antitela i njihove primene |
CN105339002B (zh) | 2013-06-10 | 2019-06-28 | 伊皮埃里安股份有限公司 | 治疗tau病变的方法 |
Family Cites Families (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US187004A (en) * | 1877-02-06 | Improvement in water-wheels | ||
JPS559099B2 (es) | 1972-08-07 | 1980-03-07 | ||
JPS4935633A (es) | 1972-08-09 | 1974-04-02 | ||
JPS5124008B2 (es) | 1972-08-10 | 1976-07-21 | ||
JPS4935632A (es) | 1972-08-10 | 1974-04-02 | ||
JPS5271481A (en) | 1975-12-10 | 1977-06-14 | Yoshitomi Pharmaceut Ind Ltd | Synthesis of pyridylpyrimidines |
JPS52139085A (en) | 1976-05-13 | 1977-11-19 | Hokuriku Pharmaceutical | 22allylpiperazine derivative and method for its preparation |
US4507302A (en) | 1979-03-19 | 1985-03-26 | The Upjohn Company | Method for treating arthritis with 6-aryl pyrimidine compounds |
US4619933A (en) | 1979-09-28 | 1986-10-28 | The Upjohn Company | 6-aryl pyrimidines for treating aplastic anemia |
US4725600A (en) | 1984-07-13 | 1988-02-16 | Fujisawa Pharmaceutical Co., Ltd. | Pyrimidine compounds having activity as a cardiotonic anti-hypertensive cerebrovascular vasodilator and anti-platelet aggregation agent |
GB8906946D0 (en) * | 1988-04-22 | 1989-05-10 | Ici Plc | Novel compounds |
DE58908208D1 (de) | 1988-07-29 | 1994-09-22 | Ciba Geigy Ag | Thiouracile als Stabilisatoren für chlorhaltige Polymerisate. |
EP0909814B1 (en) | 1991-12-06 | 2008-02-13 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Use of protein kinases for the diagnosis and treatment of Alzheimer's disease |
DE4206145A1 (de) | 1992-02-28 | 1993-09-02 | Basf Ag | Herbizide n-((pyrimidin-2-yl)aminocarbonyl)benzolfulfonamide |
JP3324611B2 (ja) | 1992-07-03 | 2002-09-17 | 三菱化学株式会社 | タウ蛋白質のリン酸化方法 |
JPH06329551A (ja) | 1993-03-22 | 1994-11-29 | Mitsubishi Kasei Corp | アルツハイマー病の予防または治療薬およびそのスクリーニング方法 |
CZ101496A3 (en) | 1993-10-12 | 1996-11-13 | Du Pont Merck Pharma | N-alkyl-n-aryl-pyrimidinamines and derivatives thereof |
AR038955A1 (es) | 1996-12-05 | 2005-02-02 | Amgen Inc | Compuestos de pirimidinona y piridona sustituidos y metodos para su uso |
US6096753A (en) | 1996-12-05 | 2000-08-01 | Amgen Inc. | Substituted pyrimidinone and pyridone compounds and methods of use |
US6410729B1 (en) | 1996-12-05 | 2002-06-25 | Amgen Inc. | Substituted pyrimidine compounds and methods of use |
BR9713863A (pt) | 1996-12-05 | 2000-03-14 | Amgen Inc | Composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, processos de profilaxia ou tratamento, para abaixar as concentrações no plasma, para diminuir a produção de prostaglandinas, e, para diminuir a atividade de enzima ciclooxigenase |
NZ335997A (en) | 1996-12-05 | 2001-08-31 | Amgen Inc | Substituted pyrimidine compounds for treating TNF and interleukin diseases |
CA2285445C (en) * | 1997-03-26 | 2007-06-12 | Taisho Pharmaceutical Co., Ltd. | 4-tetrahydropyridylpyrimidine derivative |
AR023052A1 (es) * | 1998-09-25 | 2002-09-04 | Mitsuharu Yoshimura Milton | Derivados de pirimidona |
CZ20023199A3 (cs) | 2000-02-25 | 2003-05-14 | F. Hoffmann-La Roche Ag | Modulátory receptoru adenosinu |
AU2001262150A1 (en) | 2000-03-23 | 2001-10-03 | Mitsubishi Pharma Corporation | 2-(nitrogen-heterocyclic)pyrimidone derivatives |
EP1136482A1 (en) | 2000-03-23 | 2001-09-26 | Sanofi-Synthelabo | 2-Amino-3-(alkyl)-pyrimidone derivatives as GSK3beta inhibitors |
JP4347050B2 (ja) | 2001-09-21 | 2009-10-21 | 田辺三菱製薬株式会社 | 3−置換−4−ピリミドン誘導体 |
NZ541074A (en) | 2002-12-16 | 2008-04-30 | Mitsubishi Pharma Corp | 3-Substituted-4-pyrimidone derivatives |
TWI357408B (en) | 2003-03-26 | 2012-02-01 | Mitsubishi Tanabe Pharma Corp | 3-substituted-4-pyrimidone derivatives |
-
2002
- 2002-09-20 NZ NZ531637A patent/NZ531637A/en not_active IP Right Cessation
- 2002-09-20 US US10/489,607 patent/US7572793B2/en not_active Expired - Fee Related
- 2002-09-20 DE DE60208051T patent/DE60208051T2/de not_active Expired - Lifetime
- 2002-09-20 CA CA2460177A patent/CA2460177C/en not_active Expired - Fee Related
- 2002-09-20 KR KR1020047004113A patent/KR100754596B1/ko not_active IP Right Cessation
- 2002-09-20 AU AU2002337498A patent/AU2002337498B2/en not_active Ceased
- 2002-09-20 PL PL02368816A patent/PL368816A1/xx not_active Application Discontinuation
- 2002-09-20 WO PCT/JP2002/009684 patent/WO2003027080A1/en active IP Right Grant
- 2002-09-20 MX MXPA04002661A patent/MXPA04002661A/es active IP Right Grant
- 2002-09-20 AR ARP020103546A patent/AR043700A1/es unknown
- 2002-09-20 BR BR0212893-4A patent/BR0212893A/pt not_active Application Discontinuation
- 2002-09-20 AR ARP020103547A patent/AR036604A1/es active IP Right Grant
- 2002-09-20 ES ES02772870T patent/ES2256540T3/es not_active Expired - Lifetime
- 2002-09-20 EA EA200400452A patent/EA007224B1/ru not_active IP Right Cessation
- 2002-09-20 EP EP02772870A patent/EP1427709B1/en not_active Expired - Lifetime
- 2002-09-20 JP JP2003530670A patent/JP4368682B2/ja not_active Expired - Lifetime
- 2002-09-20 HU HU0401898A patent/HUP0401898A3/hu unknown
- 2002-09-20 CN CNB028180178A patent/CN1319950C/zh not_active Expired - Fee Related
- 2002-09-20 DK DK02772870T patent/DK1427709T3/da active
- 2002-09-20 IL IL16070102A patent/IL160701A0/xx unknown
- 2002-09-20 AT AT02772870T patent/ATE312827T1/de active
- 2002-09-20 TW TW091121652A patent/TWI303171B/zh active
-
2004
- 2004-03-03 IL IL160701A patent/IL160701A/en not_active IP Right Cessation
- 2004-04-20 NO NO20041604A patent/NO326694B1/no not_active IP Right Cessation
- 2004-12-07 HK HK04109693A patent/HK1068608A1/xx not_active IP Right Cessation
-
2006
- 2006-03-09 CY CY20061100327T patent/CY1105554T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR036604A1 (es) | Derivados de 4-pirimidona 3-sustituida | |
AR046297A1 (es) | Inhibidores de la dpp - iv metodos para prepararlos y composiciones farmaceuticas que los contienen como agente activo | |
AR066460A2 (es) | Compuestos derivados de fenil-piperazina, fenil-piperidina y fenil-tetrahidropiridina como inhibidores de la reabsorcion de la serotonina, una composicion farmaceutica y utilizacion de los mismos para la preparacion de medicamentos | |
AR079541A1 (es) | Compuestos sustituidos de n-(1h-indazol-4-il) imidazo (1,2-a) piridin-3-carboxamida como inhibidores de cfms | |
RU2007149317A (ru) | Циклическое производное амина, содержащее замещенную алкильную группу | |
SV2002000504A (es) | Derivados biciclicos sustituidos para el tratamiento del crecimiento celular anormal ref.pc10760/20205/bb | |
AR050180A1 (es) | Derivados de guanidina y sus usos terapeuticos | |
AR040498A1 (es) | Indoles sustituidos utiles para el tratamiento de enfermedades respiratorias | |
AR032436A1 (es) | Oxazolidinonas substituidas, procedimiento para su preparacion, medicamentos, el uso de las mismas para la fabricacion de medicamentos, y el metodo para impedir la coagulacion sanguinea in vitro | |
BRPI0616574A2 (pt) | derivado de sulfonamida tendo atividade antagonìstica de receptor de pgd2 | |
JP2014511892A5 (es) | ||
PE20010130A1 (es) | Derivados de 3(5)-amino-pirazol y procedimiento para su preparacion | |
AR057131A1 (es) | Derivados de purina como inmunomodulador | |
DK1942108T3 (da) | Forbindelse indeholdende basisk gruppe samt anvendelse deraf | |
RU2006130000A (ru) | Органические соединения | |
CO5640104A2 (es) | Derivados de aminoisoxazol activos como inhibidores de quinasa | |
AR066972A1 (es) | Derivados azapeptidicos | |
AR057906A1 (es) | Derivados de pirimidona biciclicos sustituidos y su uso en la preparacion de medicamentos para el tratamiento de enfermedades mediadas por la actividad anormal de gsk3beta. | |
AR043658A1 (es) | Derivados 8-substituidos-6,7,8,9-tetrahidropirimido[1,2-a]pirimidin-4-ona | |
AR053082A1 (es) | DERIVADOS 8-PERFLUOROALQUIL-6,7,8,9-TETRAHIDROPIRIMIDO[1,2-A]PIRIMIDIN-4-ONA SUBSTITUIDOS NHIBIDORES DE GSK3BETA Y SU EMPLEO EN LA FABRICACIoN DE MEDICAMENTOS PARA EL TRATAMIENTO DE ENFERMEDADES NEURODEGENERATIVAS. | |
UY28787A1 (es) | Derivados de beta-aminoacidos como inhibidores del factor xa | |
AR061583A1 (es) | Acidos 6-(bencilo sustituido con heterociclil)-4-oxiquinolin carboxilicos, inhibidores de vih-integrasas, composiciones farmaceuticas que los contienen y usos como agentes anti-vih. | |
AR035651A1 (es) | Uso de derivados de indol para la manufactura de un medicamento para reducir la presion intraocular y una composicion | |
AR084430A1 (es) | Di/tri-aza-espiro-alcanos c | |
AR115303A1 (es) | Moduladores de calpaína y usos terapéuticos de los mismos |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant, registration |